SCHEMBL7134153

SCHEMBL7134153

O=C1Cc2c(cccc2OC[C@@H]2CO2)N1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 4/20 0.51
DRD4 P21917 3/20 0.51
DRD3 P35462 3/20 0.51
ALDH1A1 P00352 3/20 0.48
GLA P06280 1/20 0.48
CYP3A4 P08684 2/20 0.43
TP53 P04637 1/20 0.43
TSHR P16473 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HIF1A Q16665 1/20 0.43
TDP1 Q9NUW8 1/20 0.41
OPRK1 P41145 3/20 0.39
HTR2A P28223 2/20 0.39
HRH1 P35367 2/20 0.39
HTR2B P41595 2/20 0.39
HTR1A P08908 2/20 0.39
LMNA P02545 2/20 0.39
KDM4E B2RXH2 1/20 0.39
CHRM2 P08172 1/20 0.39
ADRA2A P08913 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9386670 1.00 DRD2 (0.51) DRD2DRD4DRD3ALDH1A1GLA
SCHEMBL4902703 0.88 ADRB1 (0.49) DRD2DRD4DRD3ALDH1A1GLA
SCHEMBL4902708 0.88 ADRB1 (0.49) DRD2DRD4DRD3ALDH1A1GLA
SCHEMBL9653148 0.88 ADRB1 (0.49) DRD2DRD4DRD3ALDH1A1GLA
SCHEMBL8054602 0.86 ALDH1A1 (0.46) DRD2DRD4DRD3ALDH1A1GLA
SCHEMBL9390026 0.78 DRD2 (0.61) DRD2DRD4DRD3CYP3A4OPRK1
SCHEMBL28870646 0.78 DRD2 (0.56) DRD2DRD4DRD3CYP3A4TP53
SCHEMBL10560457 0.78 ALDH1A1 (0.48) ALDH1A1GLACYP3A4TP53TSHR
SCHEMBL10989322 0.77 ALDH1A1 (0.44) ALDH1A1GLACYP3A4TP53TSHR
SCHEMBL14358826 0.75 DRD2 (0.61) DRD2DRD4DRD3CYP3A4OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6506901-B2 1-(9H-Carbazol-4-yloxy)-3-((1-(7-trifluoromethyl-quinolin-4-yl) -piperidin-4-lmethyl)-amino)-propan-2-ol, for example; treating diabetes, urinary continence, atherosclerosis, gastrointestinal disorders, glaucoma WYETH 2003-01-14 US disclosed
US-20020037907-A1 Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists AMERICAN HOME PRODUCTS CORPORATION (US) 2002-03-28 US disclosed
WO-2002006255-A2 HYDROXY-(PIPERIDIN-4-YL-METHYLAMINO)-ALKYL BETA-3 ADRENERGIC RECEPTOR ANTAGONISTS WYETH (US) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037907-A1 Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists GPR119, ADRB1, ADRB2 DRD2 325/4885DRD4 769/4885DRD3 393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.